T P Monath

Summary

Publications

  1. pmc Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins
    P J Giannasca
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    Infect Immun 65:4288-98. 1997
  2. pmc A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys
    F Guirakhoo
    Acambis, Inc, 38 Sidney St, Cambridge, MA 02139, USA
    J Virol 78:9998-10008. 2004
  3. ncbi request reprint Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human pr
    T P Monath
    OraVax Inc, Cambridge, MA 02139, USA
    Vaccine 17:1869-82. 1999
  4. pmc Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys
    T P Monath
    OraVax Inc, Cambridge, Massachusetts 02139, USA
    J Virol 74:1742-51. 2000
  5. ncbi request reprint Ecology of Marburg and Ebola viruses: speculations and directions for future research
    T P Monath
    Research and Medical Affairs, OraVax, Inc, Cambridge Massachusetts 02139, USA
    J Infect Dis 179:S127-38. 1999
  6. ncbi request reprint Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis
    F Guirakhoo
    OraVax, Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
    Virology 257:363-72. 1999
  7. pmc Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
    F Guirakhoo
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    J Virol 74:5477-85. 2000
  8. ncbi request reprint Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys
    C K Lee
    OraVax, Inc, Cambridge, MA, USA
    Vaccine 17:1493-505. 1999
  9. pmc Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection
    H Kleanthous
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    Infect Immun 66:2879-86. 1998
  10. ncbi request reprint Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection
    G A Myers
    OraVax Inc, Cambridge, MA 02139, USA
    Vaccine 17:1394-403. 1999

Detail Information

Publications24

  1. pmc Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins
    P J Giannasca
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    Infect Immun 65:4288-98. 1997
    ..The selective recognition of NALT M cells by a lectin in vivo provides a model for microbial adhesin-host cell receptor interactions on M cells and the targeted delivery of immunogens to NALT following intranasal administration...
  2. pmc A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys
    F Guirakhoo
    Acambis, Inc, 38 Sidney St, Cambridge, MA 02139, USA
    J Virol 78:9998-10008. 2004
    ..These changes may be responsible for virus attenuation through a change in the pH threshold for virus envelope fusion with the host cell membrane...
  3. ncbi request reprint Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human pr
    T P Monath
    OraVax Inc, Cambridge, MA 02139, USA
    Vaccine 17:1869-82. 1999
    ....
  4. pmc Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys
    T P Monath
    OraVax Inc, Cambridge, Massachusetts 02139, USA
    J Virol 74:1742-51. 2000
    ..ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy...
  5. ncbi request reprint Ecology of Marburg and Ebola viruses: speculations and directions for future research
    T P Monath
    Research and Medical Affairs, OraVax, Inc, Cambridge Massachusetts 02139, USA
    J Infect Dis 179:S127-38. 1999
    ..Such viruses may have separate life cycles or may give rise to virulent strains by mutation...
  6. ncbi request reprint Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis
    F Guirakhoo
    OraVax, Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
    Virology 257:363-72. 1999
    ..All attenuating residues and the avirulent phenotype were preserved after 18 passages in cell cultures or 6 passages in mouse brains...
  7. pmc Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
    F Guirakhoo
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    J Virol 74:5477-85. 2000
    ..The high replication efficiency, attenuation phenotype in mice and monkeys, immunogenicity and protective efficacy, and genomic stability of ChimeriVax-D2 justify it as a novel vaccine candidate to be evaluated in humans...
  8. ncbi request reprint Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys
    C K Lee
    OraVax, Inc, Cambridge, MA, USA
    Vaccine 17:1493-505. 1999
    ..This study provides the first evidence for effective vaccination of nonhuman primates against H. pylori, and preliminary evidence that a reduction in bacterial density attributable to immunization may lessen gastric inflammation...
  9. pmc Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection
    H Kleanthous
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    Infect Immun 66:2879-86. 1998
    ..pylori and equivalent for all routes. These results identify both the rectum and nasal passages as suitable inductive sites for urease immunization...
  10. ncbi request reprint Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection
    G A Myers
    OraVax Inc, Cambridge, MA 02139, USA
    Vaccine 17:1394-403. 1999
    ..This study shows that immunization with rUre plus LT results in long-lasting protective immunity against challenge with H. felis...
  11. pmc Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine
    F Guirakhoo
    Acambis, Inc, Cambridge, Massachusetts 02139, USA
    J Virol 75:7290-304. 2001
    ..However, preimmune monkeys developed either no detectable viremia or a level of viremia lower than that in nonimmune controls. This is the first recombinant tetravalent dengue vaccine successfully evaluated in nonhuman primates...
  12. ncbi request reprint Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates
    F Guirakhoo
    Acambis Inc, Cambridge, Massachusetts 02139, USA
    Virology 298:146-59. 2002
    ..This indicates that further formulations for dose adjustments need to be tested in monkeys to identify an optimal formulation for humans...
  13. pmc Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE)
    J Arroyo
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    J Virol 75:934-42. 2001
    ....
  14. ncbi request reprint Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori
    C K Lee
    OraVax Inc, Cambridge, MA 02139, USA
    Vaccine 17:3072-82. 1999
    ..However, monkeys receiving the two parenteral-only regimens had slightly elevated gastritis scores...
  15. ncbi request reprint Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent
    H Kleanthous
    Acambis, Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 19:4883-95. 2001
    ..These results suggest varied specificity for the murine host by different Helicobacter strains that can influence the outcome of both infection and immunity...
  16. pmc Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection
    R Weltzin
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    Infect Immun 68:2775-82. 2000
    ..These results show that LT and LTB stimulate qualitatively different humoral immune responses to urease but are both effective parenteral adjuvants for immunization of mice against H. pylori infection...
  17. pmc Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters
    P J Giannasca
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    Infect Immun 67:527-38. 1999
    ..These results suggest that prophylactic parenteral vaccination or intravenous immunotherapy could provide protection from C. difficile disease in humans...
  18. ncbi request reprint Yellow fever vector live-virus vaccines: West Nile virus vaccine development
    J Arroyo
    Acambis Inc 38 Sidney Street, Cambridge, MA 02319, USA
    Trends Mol Med 7:350-4. 2001
    ....
  19. ncbi request reprint Prospects for development of a vaccine against the West Nile virus
    T P Monath
    Research and Medical Affairs, Acambis Incorporated, Cambridge, Massachusetts 02139, USA
    Ann N Y Acad Sci 951:1-12. 2001
    ..The chimeric virus replicates in the host like yellow fever 17D but immunizes specifically against West Nile virus...
  20. ncbi request reprint West Nile virus vaccine
    T P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
    Curr Drug Targets Infect Disord 1:37-50. 2001
    ....
  21. ncbi request reprint Japanese encephalitis vaccines: current vaccines and future prospects
    T P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Curr Top Microbiol Immunol 267:105-38. 2002
    ..Other approaches to JE vaccines--including naked DNA, oral vaccination, and recombinant subunit vaccines--have been reviewed...
  22. ncbi request reprint Yellow fever: an update
    T P Monath
    Acambis Inc, Cambridge, Massachusetts 02139, USA
    Lancet Infect Dis 1:11-20. 2001
    ..New applications of yellow fever 17D virus as a vector for foreign genes hold considerable promise as a means of developing new vaccines against other viruses, and possibly against cancers...
  23. pmc Intranasal antibody prophylaxis for protection against viral disease
    R Weltzin
    OraVax, Inc, Cambridge, Massachusetts 02139, USA
    Clin Microbiol Rev 12:383-93. 1999
    ..Polyclonal human immunoglobulin from pooled plasma preparations can be used to provide broad protection against a number of different pathogens, while monoclonal antibodies or their fragments can be used to target specific viruses...
  24. pmc Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses
    T H Ermak
    OraVax, Inc, Cambridge, Massachusetts 02139
    J Exp Med 188:2277-88. 1998
    ..pylori infection by immunization with the urease antigen is dependent on MHC class II-restricted, cell-mediated mechanisms, and antibody responses to urease are not required for protection...